Drug Profile
MVA MERS S
Alternative Names: MERS-CoV vaccine - IDT Biologika GmbH/Ludwig-Maximilians-University; Middle East respiratory syndrome coronavirus vaccine - IDT Biologika GmbH/Ludwig-Maximilians-University; MVA-MERS-SLatest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Ludwig-Maximilians-University
- Developer Bernhard Nocht Institute for Tropical Medicine; Charite - Universitatsmedizin Berlin; Ludwig-Maximilians-University; University Medical Center Hamburg-Eppendorf; University of Cologne; University of Marburg
- Class COVID-19 vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Middle East respiratory syndrome coronavirus
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for phase-I development in Middle-East-respiratory-syndrome-coronavirus(Prevention) in Germany (IM, Injection)
- 21 Apr 2020 Adverse events and immunogenicity data from a phase I trial in Middle East respiratory syndrome coronavirus released by University Medical Center Hamburg-Eppendorf
- 21 Apr 2020 University Medical Center Hamburg-Eppendorf plans a clinical trial for COVID-2019 infections